| Should Investors Buy Oscar Health Stock Right Now? |
Healthcare stocks have been under pressure in the U.S. due to increasing regulatory headwinds and rising costs. |
fool.com |
2025-05-16 09:30:00 |
Czytaj oryginał (ang.) |
| Oscar Health: Steep Budget Cuts In 2026 Healthcare Estimates Spell Uncertainty |
I rate Oscar Health as a Hold, due to proposed steep budget cuts in the 2026 budget, impacting Medicaid and Medicare Advantage coverage. Oscar Health's impressive financials and revenue growth are overshadowed by macroeconomic risks, including potential policy changes and increased uninsured rates. Despite strong internal operations and a projected revenue CAGR of ~20% between 2024 and 2027, external factors pose significant risks to growth. |
seekingalpha.com |
2025-05-15 05:19:11 |
Czytaj oryginał (ang.) |
| Oscar Health: The Healthcare Disruptor Just Hit Its Stride |
Oscar Health, Inc. delivered strong Q1 results with 42% revenue growth, improved cost control, and expanding membership, signaling sustainable profitability and margin expansion. The company stands to benefit from competitor exits in ACA exchanges and potential policy changes lowering prescription drug costs, enhancing long-term operating leverage. Despite a high current P/E, forward multiples and consensus EPS growth suggest Oscar is undervalued with >41% upside potential in the next 12-18 months. |
seekingalpha.com |
2025-05-14 14:02:02 |
Czytaj oryginał (ang.) |
| How AI helped Oscar Health cut costs and grow |
Oscar Health (OSCR) stock has been rising since the company reported first quarter earnings results that beat estimates on both the top and bottom lines. Oscar Health also reaffirmed its full-year guidance for all metrics. |
youtube.com |
2025-05-08 22:35:16 |
Czytaj oryginał (ang.) |
| Oscar Health, Inc. (OSCR) Q1 2025 Earnings Call Transcript |
Oscar Health, Inc. (NYSE:OSCR ) Q1 2025 Earnings Conference Call May 7, 2025 8:00 AM ET Company Participants Chris Potochar - Vice President of Treasury and Investor Relations Mark Bertolini - Chief Executive Officer Scott Blackley - Chief Financial Officer Conference Call Participants John Ransom - Raymond James Stephen Baxter - Wells Fargo Jonathan Yong - UBS Joanna Gajuk - Bank of America Josh Raskin - Nephron Research Jessica Tassan - Piper Sandler Michael Ha - Baird David Windley - Jefferies Operator Good morning, everyone. My name is Ellie, and I will be your conference operator for today. |
seekingalpha.com |
2025-05-07 18:00:16 |
Czytaj oryginał (ang.) |
| Oscar Health, Inc. (OSCR) Beats Q1 Earnings and Revenue Estimates |
Oscar Health, Inc. (OSCR) came out with quarterly earnings of $0.92 per share, beating the Zacks Consensus Estimate of $0.83 per share. This compares to earnings of $0.62 per share a year ago. |
zacks.com |
2025-05-07 12:10:38 |
Czytaj oryginał (ang.) |
| Oscar Health Announces Strong Financial Results for First Quarter 2025 And Reaffirms 2025 Guidance |
NEW YORK--(BUSINESS WIRE)--Oscar Health, Inc. (“Oscar” or the “Company”) (NYSE: OSCR), a leading healthcare technology company, announced today its financial results for the first quarter ended March 31, 2025. “Oscar reported strong financial results in the first quarter,” said Mark Bertolini, CEO of Oscar Health. “We delivered continued top-line growth and bottom-line performance with significant year-over-year increases in revenue and net income. We continue to expect meaningful margin expans. |
businesswire.com |
2025-05-07 10:00:00 |
Czytaj oryginał (ang.) |
| Oscar Health, Inc. (OSCR) Stock Declines While Market Improves: Some Information for Investors |
In the closing of the recent trading day, Oscar Health, Inc. (OSCR) stood at $13.01, denoting a -1.06% change from the preceding trading day. |
zacks.com |
2025-04-30 23:05:32 |
Czytaj oryginał (ang.) |
| Oscar Health, Inc. (OSCR) Stock Falls Amid Market Uptick: What Investors Need to Know |
The latest trading day saw Oscar Health, Inc. (OSCR) settling at $11.60, representing a -0.34% change from its previous close. |
zacks.com |
2025-04-22 23:05:40 |
Czytaj oryginał (ang.) |
| Oscar Health, Inc. (OSCR) Stock Drops Despite Market Gains: Important Facts to Note |
Oscar Health, Inc. (OSCR) closed at $12.42 in the latest trading session, marking a -1.19% move from the prior day. |
zacks.com |
2025-04-14 23:20:39 |
Czytaj oryginał (ang.) |
| Oscar Health, Inc. (OSCR) Increases Despite Market Slip: Here's What You Need to Know |
In the most recent trading session, Oscar Health, Inc. (OSCR) closed at $13.61, indicating a +1.8% shift from the previous trading day. |
zacks.com |
2025-04-03 23:05:44 |
Czytaj oryginał (ang.) |
| Why Oscar Health, Inc. (OSCR) Outpaced the Stock Market Today |
In the closing of the recent trading day, Oscar Health, Inc. (OSCR) stood at $14.19, denoting a +1.65% change from the preceding trading day. |
zacks.com |
2025-03-25 21:20:31 |
Czytaj oryginał (ang.) |
| Is Trending Stock Oscar Health, Inc. (OSCR) a Buy Now? |
Oscar Health (OSCR) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects. |
zacks.com |
2025-03-21 19:45:24 |
Czytaj oryginał (ang.) |
| Oscar Health, Inc. (OSCR) Advances But Underperforms Market: Key Facts |
The latest trading day saw Oscar Health, Inc. (OSCR) settling at $12.85, representing a +0.16% change from its previous close. |
zacks.com |
2025-03-19 21:01:19 |
Czytaj oryginał (ang.) |
| Oscar Health, Inc. (OSCR) Laps the Stock Market: Here's Why |
Oscar Health, Inc. (OSCR) reachead $13.45 at the closing of the latest trading day, reflecting a +1.74% change compared to its last close. |
zacks.com |
2025-03-17 21:20:30 |
Czytaj oryginał (ang.) |
| Here's how Oscar Health CEO Mark Bertolini wants to fix the health insurance system |
Mark Bertolini, Oscar Health CEO and former Aetna chairman and CEO, discusses potential solutions to some of the problems in the health insurance industry and why he believes the individual insurance market is the solution for Americans. |
youtube.com |
2025-03-13 12:30:01 |
Czytaj oryginał (ang.) |
| Oscar Health CEO on fixing the health insurance system: Individual insurance market is the solution |
Mark Bertolini, Oscar Health CEO and former Aetna chairman and CEO, joins 'Squawk Box' to discuss potential solutions to some of the problems in the health insurance industry, why he believes the individual insurance market is the solution for Americans, and more. |
youtube.com |
2025-03-13 10:49:50 |
Czytaj oryginał (ang.) |
| Oscar Health: The Most Undervalued Small Cap But With One Big Risk |
I am bullish on Oscar Health (OSCR) due to its efficient D2C model, AI integration, and improving EBITDA margins despite high revenue growth. OSCR's opportunity in the ICHRA market is significant, with projections to increase 3x-5x by 2030, positioning it well against larger competitors. Risks include potential changes to ACA subsidies under future administrations, which could disrupt OSCR's current business model and force a shift to ICHRA. |
seekingalpha.com |
2025-03-09 15:47:44 |
Czytaj oryginał (ang.) |
| Ataraxis AI to Transform Precision Medicine in Cancer Care with $20.4 Million Series A |
NEW YORK--(BUSINESS WIRE)--Ataraxis AI, the leading AI precision medicine company, today announced its $20.4 million Series A financing led by AIX Ventures with participation from Floating Point, Thiel Bio, Founders Fund, Bertelsmann Investments, and existing investors, Giant Ventures and Obvious Ventures. The round also received backing from angel investors and healthcare pioneers, including Mario Schlosser, co-founder and former CEO of Oscar Health (NYSE: OSCR), Ryan Fukushima, COO of Tempus,. |
businesswire.com |
2025-03-05 16:13:00 |
Czytaj oryginał (ang.) |
| Oscar Health, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - OSCR |
NEW YORK, NY / ACCESS Newswire / March 4, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Oscar Health, Inc. ("Oscar Health, Inc.") (NYSE:OSCR) concerning possible violations of federal securities laws. Oscar Health reported mixed earnings performance for the fourth quarter including a greater than expected loss of $0.62 per share. |
accessnewswire.com |
2025-03-04 09:30:00 |
Czytaj oryginał (ang.) |
| OSCR ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Oscar Health, Inc. |
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Oscar Health, Inc. ("Oscar Health, Inc.") (NYSE:OSCR) concerning possible violations of federal securities laws. Oscar Health reported mixed earnings performance for the fourth quarter including a greater than expected loss of $0.62 per share. |
accessnewswire.com |
2025-02-27 09:25:00 |
Czytaj oryginał (ang.) |
| Oscar Health, Inc. Being Investigated on Behalf of Oscar Health, Inc. Investors. Contact Levi & Korsinsky For Details |
NEW YORK, NY / ACCESS Newswire / February 26, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Oscar Health, Inc. ("Oscar Health, Inc.") (NYSE:OSCR) concerning possible violations of federal securities laws. Oscar Health reported mixed earnings performance for the fourth quarter including a greater than expected loss of $0.62 per share. |
accessnewswire.com |
2025-02-26 09:30:00 |
Czytaj oryginał (ang.) |
| Shareholders that lost money on Oscar Health, Inc.(OSCR) should contact Levi & Korsinsky about Securities Fraud Investigation - OSCR |
NEW YORK, NY / ACCESS Newswire / February 25, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Oscar Health, Inc. ("Oscar Health, Inc.") (NYSE:OSCR) concerning possible violations of federal securities laws. Oscar Health reported mixed earnings performance for the fourth quarter including a greater than expected loss of $0.62 per share. |
accessnewswire.com |
2025-02-25 09:30:00 |
Czytaj oryginał (ang.) |
| Lost Money on Oscar Health, Inc. (OSCR)? Contact Levi & Korsinsky Regarding an Ongoing Investigation |
NEW YORK, NY / ACCESS Newswire / February 24, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Oscar Health, Inc. ("Oscar Health, Inc.") (NYSE:OSCR) concerning possible violations of federal securities laws. Oscar Health reported mixed earnings performance for the fourth quarter including a greater than expected loss of $0.62 per share. |
accessnewswire.com |
2025-02-24 09:30:00 |
Czytaj oryginał (ang.) |
| Shareholders That Lost Money on Oscar Health, Inc. (OSCR) Should Contact Levi & Korsinsky About Securities Fraud Investigation - OSCR |
NEW YORK, NY / ACCESS Newswire / February 21, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Oscar Health, Inc. ("Oscar Health, Inc.") (NYSE:OSCR) concerning possible violations of federal securities laws. Oscar Health reported mixed earnings performance for the fourth quarter including a greater than expected loss of $0.62 per share. |
accessnewswire.com |
2025-02-21 09:30:00 |
Czytaj oryginał (ang.) |
| Oscar Health, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details- OSCR |
NEW YORK, NY / ACCESS Newswire / February 20, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Oscar Health, Inc. ("Oscar Health, Inc.") (NYSE:OSCR) concerning possible violations of federal securities laws. Oscar Health reported mixed earnings performance for the fourth quarter including a greater than expected loss of $0.62 per share. |
accessnewswire.com |
2025-02-20 09:25:00 |
Czytaj oryginał (ang.) |
| Shareholder Rights Advocates at Levi & Korsinsky Investigate Oscar Health, Inc. (OSCR) Regarding Possible Securities Fraud Violations |
NEW YORK, NY / ACCESS Newswire / February 19, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Oscar Health, Inc. ("Oscar Health, Inc.") (NYSE:OSCR) concerning possible violations of federal securities laws. Oscar Health reported mixed earnings performance for the fourth quarter including a greater than expected loss of $0.62 per share. |
accessnewswire.com |
2025-02-19 09:30:00 |
Czytaj oryginał (ang.) |
| Michael Burry's latest stock bet is skyrocketing |
Michael Burry of ‘The Big Short' fame earned the admiration of investors all over the world by correctly predicting and profiting off of the 2008 subprime mortgage crisis. |
finbold.com |
2025-02-19 07:59:48 |
Czytaj oryginał (ang.) |
| OSCR ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Oscar Health, Inc. investment |
NEW YORK, NY / ACCESS Newswire / February 18, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Oscar Health, Inc. ("Oscar Health, Inc.") (NYSE:OSCR) concerning possible violations of federal securities laws. Oscar Health reported mixed earnings performance for the fourth quarter including a greater than expected loss of $0.62 per share. |
accessnewswire.com |
2025-02-18 09:25:00 |
Czytaj oryginał (ang.) |
| Oscar Health, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - OSCR |
NEW YORK, NY / ACCESS Newswire / February 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Oscar Health, Inc. ("Oscar Health, Inc.") (NYSE:OSCR) concerning possible violations of federal securities laws. Oscar Health reported mixed earnings performance for the fourth quarter including a greater than expected loss of $0.62 per share. |
accessnewswire.com |
2025-02-13 12:30:00 |
Czytaj oryginał (ang.) |
| Oscar Health, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - OSCR |
LOS ANGELES , Feb. 13, 2025 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of Oscar Health, Inc. ("Oscar Health" or "the Company") (NYSE: OSCR) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinent to investors. |
prnewswire.com |
2025-02-13 06:21:00 |
Czytaj oryginał (ang.) |
| Oscar Health, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - OSCR |
LOS ANGELES--(BUSINESS WIRE)--Oscar Health, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - OSCR. |
businesswire.com |
2025-02-12 19:00:00 |
Czytaj oryginał (ang.) |
| Oscar Health, Inc. (OSCR) Q4 2024 Earnings Call Transcript |
Oscar Health, Inc. (NYSE:OSCR ) Q4 2024 Earnings Conference Call February 4, 2025 5:00 PM ET Company Participants Chris Potochar – Vice President of Treasury and Investor Relations Mark Bertolini – Chief Executive Officer Scott Blackley – Chief Financial Officer Conference Call Participants Stephen Baxter – Wells Fargo Josh Raskin – Nephron Research Michael Ha – Baird Jonathan Yong – UBS Jessica Tassan – Piper Sandler Adam Ron – Bank of America Operator Good evening. My name is Rob, and I will be your conference operator today. |
seekingalpha.com |
2025-02-04 22:12:38 |
Czytaj oryginał (ang.) |
| Oscar Health Reports First Profitable Year as Digital Mix Drives Engagement |
The U.S. healthcare sector has undergone a rapid digital transformation in recent years, driven by a combination of regulatory shifts, consumer demand and technological advancements. The pandemic accelerated the adoption of telemedicine, remote monitoring and artificial intelligence (AI)-driven diagnostics, making digital health an essential component of modern care delivery. |
pymnts.com |
2025-02-04 21:54:15 |
Czytaj oryginał (ang.) |
| Oscar Health, Inc. (OSCR) Reports Q4 Loss, Lags Revenue Estimates |
Oscar Health, Inc. (OSCR) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $0.58. This compares to loss of $0.66 per share a year ago. |
zacks.com |
2025-02-04 20:46:27 |
Czytaj oryginał (ang.) |
| Oscar Health Announces Fourth Quarter and Full Year 2024 Results; Introduces Full Year 2025 Outlook |
NEW YORK--(BUSINESS WIRE)--Oscar Health, Inc. (“Oscar” or the “Company”) (NYSE: OSCR), a leading healthcare technology company, today announced its financial results for the fourth quarter and full year ended December 31, 2024. “Oscar reported positive full year 2024 results, capping the strongest year of financial performance in Company history,” said Mark Bertolini, CEO of Oscar Health. “We reported both Adjusted EBITDA and net income profitability – two significant milestones. Our strong top. |
businesswire.com |
2025-02-04 18:05:00 |
Czytaj oryginał (ang.) |
| Oscar Health, Inc. (OSCR) Stock Sinks As Market Gains: Here's Why |
In the most recent trading session, Oscar Health, Inc. (OSCR) closed at $16.28, indicating a -0.12% shift from the previous trading day. |
zacks.com |
2025-01-28 21:06:21 |
Czytaj oryginał (ang.) |
| Oscar Health, Inc. (OSCR) Stock Drops Despite Market Gains: Important Facts to Note |
In the latest trading session, Oscar Health, Inc. (OSCR) closed at $15.65, marking a -1.57% move from the previous day. |
zacks.com |
2025-01-21 21:21:29 |
Czytaj oryginał (ang.) |
| Oscar Health: Trump Uncertainty Creates Buying Opportunity |
Oscar Health's targets of a 20% revenue CAGR through 2027 and 5% operating margin imply operating income around $700m in 3 years. Despite not being profitable yet, Oscar Health is projected to achieve GAAP profitability in FY24, with EPS expected to grow to $0.51 by FY25. The key risk is the repeal of ACA by the Trump administration, which would significantly impact the affordability of health insurance premiums for individual buyers. |
seekingalpha.com |
2025-01-20 02:24:40 |
Czytaj oryginał (ang.) |
| Focus On Costs, Regulatory Outlook For Health Insurers In Q4'24 Earnings Season |
Most publicly traded US health insurers are forecast to report sequential revenue and earnings declines for the fourth quarter of 2024, according to S&P Global Market Intelligence analysis of sell-side analyst forecasts. Coming off a challenging end to 2024, the upcoming earnings season is an opportunity for managed care companies to focus on 2025 expectations and Medicare Advantage growth, according to J.P. Morgan analyst Lisa Gill. UnitedHealth and Oscar Health are expected to log sequential and year-over-year revenue growth. |
seekingalpha.com |
2025-01-16 12:50:00 |
Czytaj oryginał (ang.) |